FIELD: medicine.
SUBSTANCE: the present innovation deals with applying agonists of somatostatin receptors in case of thyroid carcinoma and, it also, deals with the method for modulating the rate of cell proliferation of medullary thyroid carcinoma (MTC) due to combined impact upon cells with either one or several agonists of somatostatin receptors of type 2 (SSTR2)or either with one or several agonists of somatostatin receptors of type 5 (SSTR5). Moreover, the mentioned SSTR5 agonist can be represented with D-Phe-Phe-Trp-D-Trp-Lys-Thr-Phe-Thr-NH2 or its pharmaceutically acceptable salt. The present innovation enables to enhance suppression of MTC cell proliferation due to antagonism between mediated SSTR2 and SSTR5 effects to the proliferation mentioned.
EFFECT: higher efficiency of modulation.
1 cl, 8 dwg, 2 tbl
Authors
Dates
2006-05-10—Published
2002-03-06—Filed